Mereo BioPharma
MREO
77 hedge funds and large institutions have $435M invested in Mereo BioPharma in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 12 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
41% more call options, than puts
Call options by funds: $3.18M | Put options by funds: $2.25M
20% more capital invested
Capital invested by funds: $362M → $435M (+$72.5M)
0.59% less ownership
Funds ownership: 14.33% → 13.75% (-0.59%)
3% less funds holding
Funds holding: 79 → 77 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$18.5M |
| 2 |
Millennium Management
New York
|
+$9.07M |
| 3 |
Morgan Stanley
New York
|
+$8.85M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$2.88M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.59M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
-$3.21M |
| 3 |
Goldman Sachs
New York
|
-$2.06M |
| 4 |
Renaissance Technologies
New York
|
-$1.89M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.88M |
MREO Hedge Fund Activity: Q3 2024 in Review
77 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2024, worth a combined $435M — up 20% from $362M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MREO and 10 opened new positions — a net loss of 2 holders — while 24 trimmed existing stakes and 19 added.
The largest buyer was Janus Henderson Group, adding an estimated $18.5M. The largest seller was Adage Capital Partners, cutting an estimated $8.59M.
- 77 institutional investors held Mereo BioPharma (MREO) as of Q3 2024, down from 79 in Q2 2024.
- Funds reported $435M of Mereo BioPharma stock for Q3 2024, up 20% quarter-over-quarter.
- 10 funds opened new Mereo BioPharma positions in Q3 2024 and 12 closed out, a net change of -2 holders.
- The largest Mereo BioPharma buyer in Q3 2024 was Janus Henderson Group, an estimated $18.5M added.
- The largest Mereo BioPharma seller in Q3 2024 was Adage Capital Partners, an estimated $8.59M sold.
Based on aggregated 13F filings for Q3 2024.